Merck and Ridgeback ’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies
KENILWORTH, N.J.& MIAMI--(BUSINESS WIRE) January 28, 2022 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced data from six preclinical studies demonstrating that molnupiravir,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Canada Health | Clinical Trials | COVID-19 | Merck | Pharmaceuticals | Study | USA Health